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ABSTRACT 
Objective. To determine the additional effects of Transcutaneous Electrical Nerve 
Stimulation (TENS) for knee osteoarthritis (OA) when combined with a group 
education and exercise programme (‘knee group’). 
Methods. The study was a randomised sham-controlled clinical trial. Patients 
referred for physiotherapy with suspected knee OA (confirmed using the American 
College of Rheumatology clinical criteria) were invited. Exclusion criteria included co-
morbidities preventing exercise, previous TENS experience and TENS 
contraindications. Prospective sample size calculations required n=67 in each trial 
arm. 224 participants (mean age 61 years, 37% men) were randomised to three 
arms: TENS & knee group (n=73); Sham TENS & knee group (n=74); knee group 
(n=77). All patients entered an evidence-based six-week group education and 
exercise programme (‘knee group’). Active TENS produced a “strong but 
comfortable” paraesthesia within the painful area and was used as much as needed 
during the six-week period. Sham TENS used dummy devices with no electrical 
output. Blinded assessment took place at baseline, 3, 6, 12 and 24 weeks. The 
primary outcome was the Western Ontario & McMaster Universities Osteoarthritis 
Index (WOMAC) function subscale at 6 weeks. Secondary outcomes included 
WOMAC pain, stiffness and total scores; extensor muscle torque; global assessment 
of change; exercise adherence; and exercise self-efficacy. Data analysis was by 
intention to treat. 
Results. All outcomes improved over time (p<0.05) but there were no differences 
between trial arms (p>0.05). All improvements were maintained at 24-week follow-
up. 
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Conclusion. There were no additional benefits of TENS, failing to support its use as 
a treatment adjunct within this context. 
 
Page 4 of 33
John Wiley & Sons, Inc.
Arthritis Care & Research
 5
SIGNIFICANCE AND INNOVATION 
• People with knee OA improved over time with a group education and exercise 
intervention.  
• Improvements included pain, stiffness, function, strength, exercise adherence, 
exercise self-efficacy and global assessment of change. 
• TENS failed to provide any additional clinical benefit and cannot be 
recommended as a treatment adjunct in this context. 
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INTRODUCTION 
Knee osteoarthritis (OA) is associated with pain, decreased range of movement and 
muscle weakness which over time may lead to functional loss (1) and substantial 
economic burden (2). 16.3% of men and 29.1% of women over 55 years exhibit 
radiographic evidence of knee OA, with age, pain and stiffness contributing to 
locomotor disability (3). Knee OA thus presents a significant source of morbidity. 
Cochrane reviews of the evidence for knee OA interventions have indicated that 
exercise is effective for both pain and function (4, 5). The latest Cochrane review 
exploring Transcutaneous Electrical Nerve Stimulation (TENS), however, was unable 
to support its effectiveness for pain relief (6). The latter review highlighted poor 
methodological quality and inadequate statistical power of existing trials, supporting 
the need for more robust randomised controlled trials (RCTs). 
Therapists often employ complex intervention packages but research into the 
effectiveness of combining treatments has been neglected (7). TENS has specifically 
been advocated as an adjunct to other treatments (8-10) and those who use TENS 
often do so in conjunction with exercise (7). Clinical guidelines also recommend 
exercise and patient education as core treatments, with TENS as an adjunct (9).  
Elucidation of the effects of TENS when combined with exercise and education is 
therefore an important clinical research question. Such effects have yet to be clearly 
established, with a limited number of previous studies in knee OA. 
One study found that TENS in combination with exercise was no better for OA 
knee pain intensity than either in isolation (11). Another trial, which met its 
prospectively calculated sample size, found that neither TENS nor interferential 
current provided additional benefits (on pain and function) over exercise alone (12). 
A third trial reported a trend towards TENS and exercise producing better 
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improvements in a range of physical outcome measures (isometric peak torque, gait 
parameters and knee range of movement) when compared with either intervention in 
isolation or sham (no current) stimulation (13), although the results failed to reach 
statistical significance. Common features of these studies are low participant 
numbers (total n=46-62; n=15-16 per trial arm) and the intermittent and brief (20-
60min) application of TENS when effectiveness may be maximised when used for 
extended periods throughout the day (10). Each study applied TENS for only four 
weeks, shorter than the minimum six weeks suggested by an earlier Cochrane 
review (14). Further, TENS was administered by therapists in the clinic when TENS 
is designed for self-administration at home (6). Suboptimal TENS dosing and 
inappropriate outcome assessment have been identified as particularly prevalent 
weaknesses indicating low fidelity in RCTs and this contributes to negative findings 
(15). A high quality trial was therefore required, with close attention to issues of 
statistical power, TENS application and outcomes assessment. 
This study is a randomised sham-controlled clinical trial designed to 
determine the additional effects of TENS in knee OA when combined with a six-week 
group education and exercise regime (‘knee group’). 
 
PATIENTS AND METHODS 
The study was conducted in accordance with the Declaration of Helsinki and 
received a favourable opinion from the Cambridgeshire 2 Research Ethics 
Committee (07/H0308/209).  
Design. This was a randomised, sham-controlled trial with 3 parallel arms: 1) 
TENS and knee group; 2) sham TENS and knee group; or 3) knee group. 
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Study population. Patients referred to physiotherapy at University Hospitals 
Bristol (UHBristol) with confirmed or suspected knee OA were eligible. Referrals 
were screened by a research associate (MD). Telephone screening was then 
conducted by MD or one of two other therapists trained in the recruitment procedure. 
The telephone interview offered referral into the knee group (routine care for knee 
OA patients at UHBristol) and gave initial verbal information about the research and 
an opportunity to ask questions. Patients who confirmed that they were interested 
were sent a patient information sheet and an appointment for a full standardised 
physiotherapy assessment with MD. 
The physiotherapy assessment aimed to ensure the knee group was clinically 
appropriate, to screen for study inclusion and exclusion criteria, and to provide 
patients with an opportunity to ask further questions. Those agreeing to enter the trial 
provided formal written consent, completed the baseline outcome measures (see 
later details), and were assigned a consecutive study number in the order in which 
they attended for assessment. They were given a date to commence the knee group 
and the participant’s study number and contact details were forwarded to the TENS 
instructors. The inclusion criteria comprised being 18 years of age or older with knee 
OA confirmed by the American College of Rheumatology (ACR) clinical criteria (16). 
The ACR criteria are knee pain accompanied by at least three from six signs and 
symptoms (age > 50 years, stiffness < 30 minutes, crepitus, bony tenderness, bony 
enlargement, no palpable warmth). Exclusion criteria were co-morbidities preventing 
participation in the knee group (17); contraindications to TENS (18); and previous 
TENS experience. Those not fulfilling the eligibility criteria or declining entry to the 
trial were referred either for individual physiotherapy treatment or to the knee group 
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as normal (but not as a study participant) according to which was considered most 
clinically appropriate.  
Randomisation. Participants were randomly assigned to one of the three trial 
arms. An independent monitor prepared sealed opaque envelopes containing 
treatment allocations. 261 envelopes were prepared with 87 allocations to each of 
the 3 treatment arms. Envelopes were mixed and then mixed again before being 
numbered consecutively. Once prepared, the trained TENS instructors were the only 
individuals to have access to the envelopes and were responsible for assigning all 
participants by opening the appropriately numbered envelope corresponding to their 
study number. All other members of the research team and clinical staff were blinded 
to allocation throughout. Before participants commenced the knee group, the TENS 
instructors contacted those allocated to active or sham TENS to arrange TENS 
training. Participants allocated to only receive the knee group intervention simply 
attended the knee group as originally scheduled. 
TENS Interventions. ‘TouchTENS’ devices (Model XL-Y1, TensCare, UK) 
were used throughout. Sham devices were deactivated by the manufacturer. All 
devices were checked by the Medical Equipment Management Organisation at 
UHBristol and were randomly assigned a device number before being employed in 
the trial. Only the TENS instructors and one member of the research team (FC) had 
access to the identity (active or sham) of individual devices. FC provided all training 
for the TENS instructors according to standardised operating procedures. FC also 
audited the processes associated with randomisation and treatment allocation, 
including periodic observation of TENS instruction sessions. 
TENS instructors were all physiotherapy technical instructors working with 
patients with musculoskeletal disorders. Four TENS instructors were employed on 
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the project to reflect the pragmatic nature of the trial. TENS instruction comprised a 
thirty-minute appointment during which patients were also assessed for competency 
to self-administer. Patients received a TENS device for their personal use from the 
date of TENS instruction and throughout the six-week duration of the knee group. 
Written and verbal information detailed the existence of different TENS devices, that 
some do not produce perceptible sensations, and that participants may receive an 
active or inactive device (in line with principles of fully informed consent). Patients 
were taught to position four electrodes around the knee joint, two on the medial and 
two on the lateral aspect either side of the joint line (such that each of the two 
electrical circuits diagonally crossed the knee). For the purposes of instruction, 
devices were set to a continuous mode (Programme A - 110Hz, 50µs). All electrical 
pulses were asymmetrical biphasic. Dummy devices (the displays were active but 
there was no current output) were used to administer sham TENS. All written and 
verbal instructions were standardised as far as possible, although patients were 
allowed to ask questions and received further instruction as required to ensure 
adequate understanding. Due to lack of evidence for the specific effects of many 
TENS parameters (19, 20, 21, 22), patients were instructed to use the device as 
much as needed (23, 24) and encouraged to try different TENS programmes. TENS 
could be used before, during or after exercise or physical function. Stimulus intensity 
is one parameter related to treatment efficacy (19, 22) therefore those receiving 
active TENS were instructed to select a stimulation intensity that generated a 'strong 
but comfortable' tingling sensation within or close to the site of pain. Those receiving 
sham TENS were instructed to select an intensity of seven or eight (within the middle 
range of the 15 settings available). TENS devices were returned to the TENS 
instructor at the end of the six-week intervention. Participants were requested not to 
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discuss their TENS treatment with research staff, clinical staff or fellow patients 
during the trial. 
Exercise intervention. Full details of the evidence-based education and 
exercise programme have previously been reported by Domaille et al (17) and it has 
been shown to be as effective as similar programmes. To reflect the pragmatic 
nature of the trial, seven therapists were trained to facilitate the knee groups. To 
maximise consistency, the same therapist aimed to lead all six sessions of each 
group. The education component was supported by a standardised presentation and 
protocol. All participants took part in the six-week knee group (17). This involved a 
group of up to 12 patients attending for one hour (30 minutes education and 30 
minutes group exercise) on six consecutive weeks. The education programme aimed 
to enhance patients' abilities to self-manage their condition. It included information 
on setting personal objectives, pacing, managing flare-ups, diet, medical 
management of OA, local community exercise opportunities and long-term exercise 
adherence. The exercise component included five minutes warm up, followed by a 
circuit of exercises aimed at improving lower limb strength, proprioception and 
function. Each exercise had specific ideas for progression which patients advanced 
as able over the six-week programme. During the first session each exercise was 
performed for one minute, with one minute between exercises to move to the next 
station. On the subsequent five sessions each exercise was performed for two 
minutes which included the time to move to the next station. All patients were taught 
home exercises during the second session and advised to perform them daily. These 
included step-ups, sit to stand, balancing on one leg and heel to toe walking. 
Increase in general physical function was a key aim of the intervention and was 
supported by individual action plans. The knee group was supported by a booklet 
Page 11 of 33
John Wiley & Sons, Inc.
Arthritis Care & Research
 12
containing written advice on the topics covered in the education session, details of 
the home exercises and tools to aid goal setting. 
Outcomes. Baseline outcome measures were taken by MD at the end of the 
initial physiotherapy assessment. Two blinded assessors (MD and another senior 
physiotherapist specialising in Rheumatology) took all other outcome measures at 
weeks 3, 6, 12 and 24. Assessments took place in the same treatment cubicle to 
standardise the environment. Participants were asked to complete all paper-based 
outcome measures prior to attending. Outcomes were chosen to meet the 
recommendations of the Outcome Measures in Rheumatology (OMERACT) core set 
(25).  
The primary outcome measure was the function subscale of the Western 
Ontario and McMaster Universities Osteoarthritis Index (WOMAC) (26) at 6 weeks. 
Although TENS is primarily used for pain relief, function was chosen to reflect the 
overall aim of the combined TENS, education and exercise package to enhance 
physical function. The total WOMAC score and pain and stiffness subscales were 
included as secondary outcome measures. The WOMAC was administered at all 
outcome points. 
Maximum knee extensor torque (as a measure of quadriceps strength) was 
measured in upright sitting (knees and hips at 90o flexion) at all outcome points using 
a digital myometer (MIE Medical Research Ltd, UK). One knee was tested, chosen 
by the patient as being the most painful. Participants undertook one practice followed 
by one assessment measure (to avoid aggravating patients’ pain). The assessor and 
participant were blinded to the myometer reading by a flap which was later 
uncovered, recorded (in Newtons) and divided by the moment arm length to give a 
torque value (in Nm). Extensor torque was the only outcome measure that was not 
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patient-reported therefore an inter-rater reliability study was conducted using the first 
12 participants entering the trial. Reliability was found to be excellent (ICC = 0.95) 
and supported the use of two blinded assessors. 
A patient global assessment of change scale (27) was used at weeks 3, 6, 12 
and 24. Patients were asked to state whether they were the same, better or worse 
compared to when they first attended the knee group. If patients chose ‘better’ or 
‘worse’ they were asked to indicate on a seven-point Likert scale by how much 
(ranging from ‘a tiny bit, almost the same’ to ‘a very great deal’).    
Self-efficacy for exercise (28) was assessed at baseline and at week 24. 
Patients were asked to respond to 4 statements about their ability and confidence to 
exercise using a five-point Likert scale (ranging from ‘strongly disagree’ to ‘strongly 
agree’). 
Self-reported exercise adherence was assessed by asking patients to indicate 
how often they undertook the daily exercises using a five-point Likert scale ranging 
from ‘never’ to ‘always’. 
Unknown to patients, TENS devices logged the cumulative duration of use 
which was retrieved on return of the device. A brief questionnaire about the settings 
used was also completed by all TENS users.  
To assess the effectiveness of blinding, assessors and exercise therapists 
were asked to guess whether or not each participant had received a TENS machine. 
Sample size. Sample size calculations were based on the WOMAC function 
subscale data presented by Tubach and colleagues (29), with data converted to 
scores out of 68 (the WOMAC function subscale total) rather than 100.  This gave 
values of mean 29.1 (SD 10.9), with the minimal clinically significant improvement 
being 6.2 out of 68. At an alpha level of 0.05 and 90% power, a minimum sample 
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size of 67 in each trial arm was calculated. Allowing for 30% attrition, a target 
recruitment of 261 participants was set (87 in each trial arm). 
Statistical analysis. Primary data analysis was by intention to treat using 
IBM SPSS Statistics Version 19. Missing values were imputed using multiple 
imputation techniques. With the exception of age and the WOMAC function subscale 
and WOMAC total score, data were not normally distributed. Log, square root and 
reciprocal transformation techniques were applied with little improvement in data 
distributions. Although deviation from normality does not preclude parametric 
analysis, a more conservative approach was taken and it was decided to use non-
parametric analyses on all data which deviated from a normal distribution. Changes 
over time and between trial arms were investigated using a general linear model 
repeated measures or non-parametric Kruskal Wallis and Friedman tests as 
appropriate. All data analysis was performed blind to trial arm allocations. 
 
RESULTS 
Recruitment and retention. Figure 1 illustrates the recruitment and retention of 
study participants. Telephone screening effectively identified potential participants 
who were ineligible, no longer needed treatment, were unwilling, or had difficulty 
attending. Table 1 illustrates that randomisation resulted in largely comparable trial 
arms (on the basis of demographic information and baseline outcome measures). 
The only potential exception was extensor torque, with participants receiving active 
TENS displaying slightly lower baseline values. Total loss to follow-up was 13% at 
six weeks and 22% at 24 weeks. Loss to follow-up was slightly higher in the knee 
group when compared to either of the TENS groups. The reasons for withdrawal 
failed to identify why, although more people in this trial arm failed to give a reason 
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and some may have been disappointed not to have received TENS. Five patients 
were not issued with TENS devices – one (active TENS) due to scheduling problems 
and four (two active and two sham TENS) who withdrew after baseline assessment. 
All were still included as part of an intention to treat analysis. 
Primary Outcome. Results for the primary outcome measure of WOMAC 
function, along with the total WOMAC score, are presented in Table 2. There was a 
clear trend of improvement over time in both outcomes but little obvious difference 
between groups. Improvements over time for each score were statistically significant 
(both p<0.001) but differences between trial arms or time x arm interaction effects 
were not (all p>0.05). Table 3 presents the proportion of patients in each trial arm 
who met the clinically significant threshold of improvement of >6.2 points on the 
WOMAC function subscale at the primary outcome point of six weeks. A slightly 
greater proportion of those who received exercise in isolation achieved this 
magnitude of improvement. The pooled standardised effect size from baseline (using 
data for all n=224 participants) was 0.30 at both week 6 and week 24. 
Secondary outcomes. Table 4 shows clear improvements over time in the 
secondary outcomes of WOMAC pain, WOMAC stiffness, extensor torque, self-
reported global change and exercise self-efficacy, but no obvious differences 
between groups. Reported exercise adherence did not seem to change over time. 
Statistical analysis confirmed that there were no statistically significant differences 
between trial arms (all p>0.05 at each time point), although each of the secondary 
outcomes improved over time (all p<0.05). 
Blinding. Questionnaires about how patients used TENS were returned by 
74% (n=54/73) of participants in the active TENS arm and 81% (n=60/74) in the 
sham TENS arm. Of those who predicted whether they had received an active or 
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inactive device (participants had to choose one or the other), 92% (n=46/50) of 
active TENS users guessed correctly. Correct identification in the sham TENS arm 
was only slightly better than chance at 60% (n=36/60). Data on blinding of the 
assessor and exercise therapists were available for 51% (n=114/224) and 35% 
(n=78/224) respectively. They were asked whether or not they thought individual 
participants had a TENS machine (regardless of whether it was active or sham). The 
proportion of correct responses was worse than chance, at 43% for the assessor 
(n=49/114) and 30% (n=23/78) for the exercise therapists. 
TENS usage. TENS usage (as logged by the devices) was available for 88% 
of active TENS users (n=64/73) and 93% (n=69/74) of sham TENS users.  Median 
logged usage was 46.5 and 39.0 hours for active and sham TENS respectively 
(Mann-Whitney U Test p=0.861). The self-reported settings “normally used” used by 
participants are presented in Table 5. Data for this question was available for 67% 
(n=49/73) and 72% (n=53/74) of active and sham TENS users respectively. The 
results show a large variation in settings used by participants in each trial arm.  
 
DISCUSSION 
This investigation found that using TENS as an adjunct to a six-week group 
education and exercise programme failed to elicit additional clinical benefits. 33% of 
active TENS users achieved the pre-specified clinically significant improvement in 
function, slightly lower than sham TENS (36%) or the knee group in isolation (42%).  
These results support previous but inconclusive findings of a lack of additional 
effect of TENS when combined with exercise for pain intensity (11) and for pain and 
function (12). Another study observed a non-statistically significant trend towards 
TENS and exercise improving a range of physical outcome measures (13). The 
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present investigation failed to substantiate those trends. The present findings concur 
with those of the most recent Cochrane review on the effectiveness of TENS for OA 
knee pain (6), although it should be noted that our study focussed on identifying 
adjunctive rather than isolated benefits of TENS. 
Alternative explanations for the findings could be that the trial was not 
sensitive enough to detect any additional benefit of TENS from that achieved by the 
knee group, or that the knee group reduced symptoms to a level that would not 
benefit from TENS. However, although the variability of baseline WOMAC function 
scores was slightly greater than the values used for the prospective sample size 
calculation (reducing statistical power to 80%), this was considered acceptable and 
there was certainly no trend suggestive of TENS benefits.  
The knee group intervention seems effective, with improvements in all 
outcome measures over time, although it should be noted that this investigation was 
not specifically designed to assess the efficacy of the knee group.  Nonetheless, the 
standardised effect size of 0.30 for the primary function outcome at both week six 
and week 24 suggests moderate treatment effects, similar in magnitude to 
nonsteroidal anti-inflammatory drugs (30). It is slightly less than the effect size of 
0.37 at six weeks observed by Domaille and colleagues (17) using the same knee 
group intervention, although the present cohort was slightly less disabled and 
arguably had less scope for improvement. The effect size was comparable to that 
observed by Hurley and colleagues (31) (0.28 at six months) whose intervention was 
adapted (17) and employed in the present investigation. 
The study blinded the outcome assessor and exercise therapists effectively to 
treatment allocation. Blinding patients to the sham intervention was relatively 
successful, with 40% believing that it was active (compared to 50% expected by 
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chance). This was, however, much less than the 92% of active TENS users who 
correctly identified that their device was active and the 84% of sham TENS users 
who thought they had an active device achieved by Deyo and colleagues (32). Due 
to the lack of additional effect of either active or sham TENS, patient blinding issues 
are not thought to have affected the trial outcome. Interestingly, the logged usage of 
sham and active TENS devices was comparable and a wide range of programmes 
were used (Table 5), suggesting a high level of interaction with, and use of, sham 
TENS devices.  
The lack of standardisation of TENS parameters may be seen by some as a 
limitation but was designed to encourage patients to engage with the devices. It is 
known that individual patients experiment with TENS devices to find settings that suit 
them (19) and this was evidenced by the wide range of settings used in the present 
study (Table 5). There is currently a lack of evidence for the effects of many specific 
parameters (19, 20, 21, 22) and therefore prescribed use may discourage 
engagement with TENS devices. More formal verification of device parameters than 
was conducted in this study would be required to identify their importance.  
It would be interesting in the future to more fully explore the interaction 
between TENS use and exercise adherence. Anecdotal evidence suggested some 
practical issues with TENS use, such as leads pulling and pads peeling off. It is also 
conceivable that TENS use might engender a slightly more passive approach to self-
management. Both issues have the potential to reduce engagement with exercise. 
Although the limited data suggested no difference in exercise adherence between 
groups, a much more nuanced approach to assessing exercise adherence might 
help to determine if and how TENS affects engagement with exercise. Identification 
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of predictors of TENS outcome could be a further important focus for future research 
(33, 34).  
In conclusion, the findings fail to support the use of TENS as an adjunct to a 
group education and exercise intervention. 
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TABLES 
Variable Active 
TENS & 
knee group 
(n=73) 
Sham TENS 
& 
knee group 
(n=74) 
Knee group 
(n=77) 
Total 
(n=224) 
Sex, women:men 47:26 49:25 45:32 141:83 
Study knee, left:right 37:36 36:38 38:39 111:113 
Age, years, mean (SD) 61.2 (11.4) 60.9 (10.8) 62.0 (9.4) 61.4 (10.5) 
Body Mass Index 29.7 (11.1) 29.1 (9.0) 29.8 (7.4) 29.6 (8.4) 
Pain duration, years 4.4 (8.7) 4.0 (8.7) 3.8 (9.8) 4.0 (8.7) 
WOMAC total, max 96, 
mean (SD) 
41.7 (19.2) 41.0 (17.6) 39.0 (18.1) 40.5 (18.2) 
WOMAC function, max 
68, mean (SD) 
29.3 (14.0) 28.8 (13.0) 27.5 (13.5) 28.5 (13.5) 
WOMAC pain 9.0 (6.0) 9.0 (5.0) 8.0 (5.8) 9.0 (6.0) 
WOMAC stiffness 4.0 (2.0) 4.0 (2.0) 4.0 (2.0) 4.0 (2.0) 
Extensor torque, Nm 42.0 (40.2) 47.8 (34.9) 45.1 (54.6) 45.0 (45.1) 
Exercise self-efficacy, 
max 20 
14.6 (4.0) 15.0 (3.9) 14.6 (3.5) 15.0 (4.0) 
Exercise beliefs 62.2 (8.1) 63.0 (10.2) 62.0 (10.8) 63.0 (9.6) 
Table 1. Participant characteristics and median baseline values for outcome 
measures. All figures are median (IQR) except where otherwise specified.
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Outcome Trial arm Baseline Week 3 Week 6 Week 12 Week 24 Effects  
WOMAC 
function, 
max 68 
Active TENS & knee group 
(n=73) 
29.3 (14.0) 26.2 (13.8) 26.4 (15.0) 25.3 (14.1) 25.8 (13.8) Time p<0.001* 
Arm p=0.413 
Time x arm 
p=0.528 
Sham TENS & knee group 
(n=74) 
28.8 (13.0) 26.9 (14.0) 25.1 (13.9) 25.7 (14.1) 25.3 (15.0) 
Knee group (n=77) 27.5 (13.5) 24.4 (11.6) 22.2 (12.1) 24.3 (11.9) 22.6 (13.4) 
WOMAC 
total, max 96 
Active TENS & knee group 
(n=73) 
41.7 (19.2) 37.4 (18.8) 37.3 (20.4) 36.2 (19.4) 36.7 (19.5) Time p<0.001* 
Arm p=0.363 
Time x arm 
p=0.541 
Sham TENS & knee group 
(n=74) 
41.0 (17.6) 38.7 (18.4) 35.7 (18.9) 36.4 (19.5) 35.7 (20.6) 
Knee group (n=77) 39.0 (18.1) 34.9 (15.9) 31.7 (16.7) 34.4 (16.6) 31.8 (18.4) 
Table 2. WOMAC function (the primary outcome measure) and WOMAC total scores over time for each trial arm. All figures 
are mean (SD). A reduction in scores indicates an improvement in the condition. Effects of time, trial arm and time x arm interaction 
were tested using a general linear model repeated measures. *Statistically significant. Post hoc analyses of changes over time did 
not provide any novel findings and have therefore been excluded in the interests of brevity and because this was not the primary 
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focus of investigation. As the overall effect of trial arm was non-significant, between-group comparisons at each time point have not 
been explored. 
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Variable Active TENS & 
knee group 
(n=73) 
Sham TENS & 
knee group 
(n=74) 
Knee group 
(n=77) 
% improving by >6.2 points 33.2% 35.9% 41.6% 
 
Table 3. Proportion of patients in each trial arm who met the clinically 
significant difference of 6.2/68 points on the WOMAC function subscale at six 
weeks. 
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Outcome Trial arm Baseline Week 3 Week 6 Week 12 Week 24 
Effect of 
time 
WOMAC Pain Active TENS & knee 
group (n=73) 
9.0 (6.0) 7.5 (7.0) 6.0 (5.0) 7.0 (7.8) 7.0 (8.0) 
p<0.001* Sham TENS & knee group 
(n=74) 
9.0 (5.0) 8.0 (6.0) 8.0 (7.0) 7.0 (7.0) 6.0 (8.0) 
Knee group (n=77) 8.0 (5.8) 7.0 (5.8) 6.0 (5.0) 6.0 (6.3) 6.0 (7.0) 
 Effect of trial arm p=0.590 p=0.537 p=0.465 p=0.386 p=0.226  
WOMAC Stiffness Active TENS & knee 
group (n=73) 
4.0 (2.0) 4.0 (2.0) 3.0 (3.0) 4.0 (3.0) 3.5 (3.0) 
p<0.001* Sham TENS & knee group 
(n=74) 
4.0 (2.0) 4.0 (3.0) 4.0 (2.0) 4.0 (3.0) 3.0 (3.0) 
Knee group (n=77) 4.0 (2.0) 3.0 (2.0) 3.0 (2.5) 3.0 (3.0) 3.0 (2.5) 
 Effect of trial arm p=0.503 p=0.538 p=0.201 p=0.527 p=0.510  
Extensor torque, Active TENS & knee 42.0 (40.2) 47.6 (56.0) 49.2 (51.5) 51.5 (45.2) 53.9 (44.6) p<0.001* 
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Nm group (n=73) 
Sham TENS & knee group 
(n=74) 
47.8 (34.9) 49.4 (41.9) 56.6 (35.8) 53.9 (44.4) 58.9 (39.7) 
Knee group (n=77) 45.1 (54.6) 55.6 (52.6) 62.0 (60.5) 58.7 (53.0) 62.2 (62.2) 
 Effect of trial arm p=0.440 p=0.748 p=0.788 p=0.660 p=0.419  
Global assessment 
of change, -7 to +7 
Active TENS & knee 
group (n=73) 
- 
2.0 (3.1) 3.0 (3.5) 2.0 (5.6) 2.8 (5.8) 
p<0.001* Sham TENS & knee group 
(n=74) 
- 
2.0 (3.7) 2.9 (4.4) 2.7 (5.4) 2.9 (6.4) 
Knee group (n=77) - 2.0 (3.0) 3.0 (4.8) 2.0 (5.0) 3.2 (5.3) 
 Effect of trial arm - p=0.212 p=0.590 p=0.785 p=0.595  
Exercise Self-
Efficacy, 5 to 20 
Active TENS & knee 
group (n=73) 
14.6 (4.0) - 
- - 
15.8 (4.5) 
p=0.031* Sham TENS & knee group 
(n=74) 
15.0 (3.9) - 
- - 
16.0 (4.1) 
Knee group (n=77) 14.6 (3.5) - - - 16.0 (5.5) 
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 Effect of trial arm p=0.693 - - - p=0.259  
Exercise 
Adherence, 0 to 4 
Active TENS & knee 
group (n=73) 
- 3.0 (1.1) 3.0 (1.0) 3.0 (1.0) 3.0 (1.0) 
p<0.001* Sham TENS & knee group 
(n=74) 
- 3.0 (1.0) 3.0 (0.3) 3.0 (1.0) 3.0 (1.0) 
Knee group (n=77) - 3.0 (1.6) 3.0 (1.9) 3.0 (1.0) 3.0 (1.2) 
 Effect of trial arm - p=0.555 p=0.391 p=0.292 p=0.159  
Table 4. Secondary outcome scores over time for each trial arm. All figures are median (IQR). A reduction in WOMAC pain and 
stiffness scores indicates an improvement in the condition. An increase in all other scores indicates improvement. Effects of trial 
arm were tested using Kruskal Wallis tests and time effects using Friedman tests. As there were no trial arm effects for any 
outcome measure, the effects of time were calculated using all participants (n=224). *Statistically significant. Post hoc analyses of 
changes over time did not provide any novel findings and have therefore been excluded in the interests of brevity and because this 
was not the primary focus of investigation. 
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TENS Programme Active 
TENS 
Sham 
TENS 
A. Continuous - 110Hz (50µs)* 22% 17% 
B. Continuous - 4Hz (200µs) 8% 8% 
C. Burst - Frequency within burst=100Hz (200µs); Repetition 
Frequency of bursts=2Hz 
20% 8% 
D. Continuous - 10Hz (200µs) 12% 11% 
E. Continuous - 110Hz (200µs) 2% 6% 
F. Intensity Modulation - 110Hz (200µs) 2% 9% 
G. Frequency Modulation - 2Hz, 10Hz, 50Hz, 80Hz, 90Hz, 
100Hz and 110Hz (200µs) 
4% 21% 
Combination 29% 21% 
Table 5. Settings reported by TENS users as those that they “normally used”. 
Please note that patients were asked to choose the TENS programme letter identifier 
as this was all that was visible to participants on the device display. Additional TENS 
parameter details are included here for clarity. *Setting A was used for initial 
instruction but participants were encouraged to try other settings throughout the six-
week TENS intervention. 
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FIGURE LEGEND 
 
Figure 1. Flowchart of recruitment and retention of study participants. Data 
analysis was by intention to treat using multiple imputation therefore n=224 data sets 
were available for analysis.  
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FIGURE 
 
Figure 1. Flowchart of recruitment and retention of study participants. Data 
analysis was by intention to treat using multiple imputation therefore n=224 data sets 
were available for analysis.  
Referrals screened (n=475) 
Telephone screened (n=433) 
Randomised (n=224) 
Active TENS & knee group (n=73) Sham TENS & knee group (n=74) 
Exercise (n=77) 
Assessed (n=67) 
Lost to follow-up (n=6) 
Assessed (n=65) 
Lost to follow-up (n=9) 
Assessed (n=63) 
Lost to follow-up (n=14) 
Assessed (n=58) 
Lost to follow-up (n=9) 
Assessed (n=61) 
Lost to follow-up (n=4) 
Assessed (n=55) 
Lost to follow-up (n=8) 
6-week 
assessment 
24-week 
assessment 
Excluded (n=42) 
Not meeting inclusion criteria (n=14) 
Multiple joint problems (n=16) 
Other reasons (n=12) 
Excluded (n=154) 
Not meeting inclusion criteria (n=64) 
Declined exercise group (n=36)  
Difficulty attending (n=27) 
Treatment no longer required (n=13) 
Declined study (n=2) 
Other reasons (n=12) 
Baseline assessment (n=279) 
 
 
 
Allocation 
 
 
 
 
 
 
 
 
 
 
Enrolment 
Excluded (n=55) 
Not meeting inclusion criteria (n=26) 
Declined study (n=23) 
Difficulty attending (n=1) 
Other reasons (n=5) 
Knee group  
(n=77) 
Total lost to follow-up (n=15) 21% 
No reason (n=7) 
Work and family commitments (n=3) 
Other medical problem (n=1) 
Difficulty attending (n=1) 
Died (n=1) 
Other reasons (n=2) 
Total lost to follow-up (n=13) 18% 
No reason (n=5) 
Work and family commitments (n=3) 
Knee surgery (n=2) 
Other medical problem (n=1) 
Difficulty attending (n=1) 
Other reasons (n=1) 
Total lost to follow-up (n=22) 29% 
No reason (n=12) 
Work and family commitments (n=6) 
Knee surgery (n=3) 
Other medical problem (n=1) 
Page 33 of 33
John Wiley & Sons, Inc.
Arthritis Care & Research
